| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_ITCH_0005000 | Exon-Exon | chr20:32981597-33000445 | chr20:34393791-34412639 | 358 nt | 0.3994 |
| hsa_ITCH_0005100 | Exon-Exon | chr20:32981597-33005045 | chr20:34393791-34417239 | 619 nt | 0.4313 |
| hsa_ITCH_0005600 | Exon-Exon | chr20:32981597-33028149 | chr20:34393791-34440344 | 281 nt | 0.4555 |
| hsa_ITCH_0005700 | Exon-Exon | chr20:32981597-33037285 | chr20:34393791-34449480 | 91 nt | 0.4505 |
| hsa_ITCH_0005200 | Exon-Exon | chr20:32981597-33045279 | chr20:34393791-34457474 | 1439 nt | 0.4496 |
| hsa_ITCH_0005800 | Exon-Exon | chr20:32981597-33059320 | chr20:34393791-34471515 | 163 nt | 0.4294 |
| hsa_ITCH_0004900 | Exon-Exon | chr20:32981597-33069011 | chr20:34393791-34481206 | 2237 nt | 0.4287 |
| hsa_ITCH_0005900 | Exon-Exon | chr20:32981597-33080402 | chr20:34393791-34492597 | 293 nt | 0.4232 |
| hsa_ITCH_0006000 | Exon-Exon | chr20:32981597-33095713 | chr20:34393791-34507908 | 137 nt | 0.4526 |
| hsa_ITCH_0006100 | Intron-Exon-Intron | chr20:32985014-33001685 | chr20:34397208-34413879 | 263 nt | 0.3802 |
A review consolidating research in humans and model organisms indicates that the circITCH functions as a tumor suppressor in glioma by sponging miR-214 to allow expression of ubiquitin-protein ligase E3, thereby suppressing proliferation and preventing apoptosis, while also targeting the Wnt/β-catenin pathway [Mehta et al. DOI:10.1016/j.pneurobio.2020.101746]. In oesophageal squamous cell carcinoma, the circITCH is downregulated and increases ITCH expression to inhibit the Wnt/β-catenin pathway [Lee et al. DOI:10.1016/j.biopha.2018.12.052]. circITCH hsa_circ_0001141 (circITCH) was found to be lower in the hearts of cancer patients suffering from doxorubicin-induced cardiomyopathy compared to those with dilated cardiomyopathy, hypertrophic cardiomyopathy, and healthy donors, and its expression ameliorates doxorubicin-induced cardiomyocyte injury [Tian et al. DOI:10.3390/molecules26041155].